Nuvalent Vergangene Ertragsentwicklung

Vergangenheit Kriterienprüfungen 0/6

Die Erträge von Nuvalent sind jährlich um durchschnittlich -49.1% zurückgegangen, während in der Branche Biotechs die Erträge jährlich um gewachsen sind und sich dabei auf 15.5% belaufen.

Wichtige Informationen

-49.1%

Wachstumsrate der Gewinne

43.6%

EPS-Wachstumsrate

Biotechs Wachstum der Industrie	17.0%
Wachstumsrate der Einnahmen	n/a
Eigenkapitalrendite	-21.6%
Netto-Marge	n/a
Letzte Ertragsaktualisierung	31 Mar 2024

Jüngste Aktualisierungen vergangener Leistungen

Keine Aktualisierungen

Recent updates

Nuvalent: Making Precise Progress In Its Oncology Pipeline

Jun 24

Nuvalent: NVL-655 Could Bring Blockbuster Potential

Jun 14

Here's Why We're Not Too Worried About Nuvalent's (NASDAQ:NUVL) Cash Burn Situation

Apr 22

Here's Why We're Not At All Concerned With Nuvalent's (NASDAQ:NUVL) Cash Burn Situation

Jun 10

We're Interested To See How Nuvalent (NASDAQ:NUVL) Uses Its Cash Hoard To Grow

Feb 24

Here's Why We're Not Too Worried About Nuvalent's (NASDAQ:NUVL) Cash Burn Situation

Sep 13

Nuvalent GAAP EPS of -$0.38 beats by $0.03

Aug 10

Here's Why We're Not At All Concerned With Nuvalent's (NASDAQ:NUVL) Cash Burn Situation

May 28

We're Hopeful That Nuvalent (NASDAQ:NUVL) Will Use Its Cash Wisely

Oct 29

Aufschlüsselung der Einnahmen und Ausgaben

Wie Nuvalent Geld verdient und ausgibt. Basierend auf den neuesten gemeldeten Einnahmen der letzten zwölf Monate.

Gewinn- und Umsatzhistorie

NasdaqGS:NUVL Einnahmen, Ausgaben und Erträge (USD Millions)
Datum	Umsatz	Allgemeine und Verwaltungskosten	F&E-Ausgaben
31 Mar 24	-146	42	130
31 Dec 23	-126	36	113
30 Sep 23	-114	32	101
30 Jun 23	-100	28	86
31 Mar 23	-89	25	73
31 Dec 22	-82	22	64
30 Sep 22	-73	20	54
30 Jun 22	-66	18	49
31 Mar 22	-57	15	43
31 Dec 21	-46	10	36
30 Sep 21	-36	7	27
30 Jun 21	-28	4	22
31 Mar 21	-27	2	18
31 Dec 20	-15	2	15

Qualität der Erträge: NUVL ist derzeit unrentabel.

Wachsende Gewinnspanne: NUVL ist derzeit unrentabel.

Analyse von freiem Cashflow und Gewinn

Analyse des Gewinnwachstums in der Vergangenheit

Ergebnisentwicklung: NUVL ist unrentabel, und die Verluste haben in den letzten 5 Jahren mit einer Rate von 49.1% pro Jahr zugenommen.

Beschleunigtes Wachstum: Das Gewinnwachstum des letzten Jahres kann nicht mit dem 5-Jahres-Durchschnitt von NUVL verglichen werden, da das Unternehmen derzeit nicht profitabel ist.

Erträge im Vergleich zur Industrie: NUVL ist unrentabel, was einen Vergleich des Gewinnwachstums des letzten Jahres mit der Branche Biotechs (-14.4%) erschwert.

Eigenkapitalrendite

Hohe Eigenkapitalrendite: NUVL hat eine negative Eigenkapitalrendite (-21.56%), da es derzeit unrentabel ist.

Nuvalent Vergangene Ertragsentwicklung

Vergangenheit Kriterienprüfungen 0/6

Wichtige Informationen

Jüngste Aktualisierungen vergangener Leistungen

Recent updates

Nuvalent: Making Precise Progress In Its Oncology Pipeline

Independent Director notifies of intention to sell stock

Nuvalent: NVL-655 Could Bring Blockbuster Potential

Chief Legal Officer & Secretary exercised options and sold US$528k worth of stock

Nuvalent, Inc. Receives U.S. FDA Breakthrough Therapy Designation for NVL-655

Nuvalent, Inc., Annual General Meeting, Jun 12, 2024

Here's Why We're Not Too Worried About Nuvalent's (NASDAQ:NUVL) Cash Burn Situation

Price target increased by 10% to US$102

Independent Director notifies of intention to sell stock

Price target increased by 8.6% to US$92.13

Nuvalent: Pivotal NSCLC Programs Progressing With Additional Data In 2024

Price target increased by 7.4% to US$84.83

Nuvalent, Inc. Initiates the Phase 2 Portion of Alkove-1 Clinical Trial for Patients with Alk-Positive Nsclc and Other Solid Tumors

Is Nuvalent, Inc. (NASDAQ:NUVL) Trading At A 36% Discount?

Chief Development Officer notifies of intention to sell stock

Founder notifies of intention to sell stock

Chief Development Officer notifies of intention to sell stock

New minor risk - Share price stability

Price target increased by 11% to US$59.14

Companies Like Nuvalent (NASDAQ:NUVL) Can Afford To Invest In Growth

Nuvalent to Present Preliminary Data from ALKOVE-1 Phase 1/2 Clinical Trial of NVL-655 at 35th AACR-NCI-EORTC Symposium

Nuvalent Initiates the Phase 2 Portion of ARROS-1 Clinical Trial for Patients with Ros1-Positive NSCLC and Other Solid Tumors

New major risk - Revenue and earnings growth

Price target increased by 8.7% to US$50.83

Chief Legal Officer & Secretary notifies of intention to sell stock

Price target increased by 8.7% to US$50.80

Chief Legal Officer & Secretary notifies of intention to sell stock

Chief Development Officer notifies of intention to sell stock

Here's Why We're Not At All Concerned With Nuvalent's (NASDAQ:NUVL) Cash Burn Situation

Chief Development Officer exercised options and sold US$125k worth of stock

Price target increased by 10% to US$46.75

Chief Development Officer exercised options and sold US$113k worth of stock

Chief Development Officer exercised options and sold US$77k worth of stock

Chief Development Officer exercised options and sold US$86k worth of stock

We're Interested To See How Nuvalent (NASDAQ:NUVL) Uses Its Cash Hoard To Grow

Chief Legal Officer & Secretary notifies of intention to sell stock

Chief Development Officer exercised options and sold US$85k worth of stock

Chief Legal Officer & Secretary exercised options and sold US$51k worth of stock

Chief Development Officer exercised options and sold US$121k worth of stock

Nuvalent Inc. Announces Publication in Cancer Discovery Detailing Design and Characterization of ROS1-selective inhibitor NVL-520

Chief Development Officer exercised options and sold US$130k worth of stock

Price target increased to US$43.67

High number of new directors

Chief Legal Officer & Secretary exercised options and sold US$287k worth of stock

Nuvalent, Inc. Reports Preliminary Phase 1 Clinical Data from ARROS-1 Trial that Support Best-In-Class Potential of NVL-520 for Patients withROS1-Positive NSCLC

Chief Development Officer exercised options and sold US$85k worth of stock

Nuvalent, Inc. Currently Enrolling Patients in the Phase 1 Portion of Its Arros-1 Study, A Phase 1/2 Clinical Trial

Chief Development Officer exercised options and sold US$72k worth of stock

Here's Why We're Not Too Worried About Nuvalent's (NASDAQ:NUVL) Cash Burn Situation

Nuvalent, Inc. Present Preliminary Phase 1 Data from ARROS-1 Clinical Trial of NVL-520 at 34th EORTC-NCI-AACR Symposium and Announces Pipeline Updates

Nuvalent GAAP EPS of -$0.38 beats by $0.03

Nuvalent, Inc. Presents New Preclinical Data Supporting Potential Best-In-Class Profile for ALK-Selective Inhibitor NV-655 At IASLC 2022 World Conference on Lung Cancer Annual Meeting

Nuvalent, Inc. Announces Leadership Promotions

Insider exercised options and sold US$278k worth of stock

Nuvalent, Inc.(NasdaqGS:NUVL) dropped from Russell 2000 Growth Index

Nuvalent, Inc. Announces Clinical Progress on Parallel Lead Programs NVL-520 and NVL-655 for NSCLC and Solid Tumor Cancers

Here's Why We're Not At All Concerned With Nuvalent's (NASDAQ:NUVL) Cash Burn Situation

Now 21% undervalued after recent price drop

Chief Medical Officer exercised options to buy US$117k worth of stock.

Now 25% undervalued after recent price drop

Nuvalent, Inc., Annual General Meeting, Jun 16, 2022

High number of new directors

High number of new directors

Nuvalent, Inc. Appoints Anna Protopapas as Chair of Board of Directors

Nuvalent to Present New Preclinical Data on ROS1-Selective Inhibitor NVL-520 and ALK-Selective Inhibitor NVL-655 at AACR Annual Meeting 2022

Insider exercised options and sold US$68k worth of stock

Nuvalent Appoints Emily Drabant Conley to Board of Directors

Nuvalent, Inc Announces First Patient Dosed in ARROS-1 Phase 1/2 Clinical Trial of NVL-520, its Novel ROS1-selective Inhibitor

We're Hopeful That Nuvalent (NASDAQ:NUVL) Will Use Its Cash Wisely

Aufschlüsselung der Einnahmen und Ausgaben

Gewinn- und Umsatzhistorie

Analyse von freiem Cashflow und Gewinn

Analyse des Gewinnwachstums in der Vergangenheit

Eigenkapitalrendite

Kapitalrendite